Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation

Transplantation

Volumn 83, Issue 11, 2007, Pages 1509-1512

  Thomas, Philip G ^a   Woodside, Kenneth J ^a   Lappin, Jacqueline A ^a   Vaidya, Smita ^a   Rajaraman, Srinivasan ^a   Gugliuzza, Kristene K ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alemtuzumab; Antithymocyte globulin; Campath 1H; High panel reactive antibody; Prospective randomized controlled trial; Renal transplantation; Tacrolimus; Thymoglobulin; Tolerogenic induction; Transplant induction

Indexed keywords

ALEMTUZUMAB; DIPHENHYDRAMINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT INFECTION; GRAFT PERFUSION; GRAFT SURVIVAL; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MALIGNANT NEOPLASTIC DISEASE; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUSTULE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSPLANTATION TOLERANCE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VIRUS MENINGITIS; WOUND INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RISK FACTORS; STEROIDS; TACROLIMUS; TRANSPLANTATION TOLERANCE;

EID: 34250658405     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000263344.53000.a1     Document Type: Article

References (19)

1. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.
2. Tippner C, Nashan B, Hoshino K, et al. Clinical and subclinical acute rejection early after liver transplantation: Contributing factors and relevance for the long-term course. Transplantation 2001; 72: 1122.
3. Wolf G, Thaiss F, Stahl RA. Cyclosporine stimulates expression of transforming growth factor-beta in renal cells. Possible mechanism of cyclosporines antiproliferative effects. Transplantation 1995; 60: 237.
4. Woodside KJ, Hu M, Meng T, Hunter GC, Sower LE, Daller JA. Differential effects of interleukin-2 blockade on apoptosis in naive and activated human lymphocytes. Transplantation 2003; 75: 1631.
5. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006; 19: 705.
6. Morris PJ, Russell NK. Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 2006; 81: 1361.
7. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505.
8. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6: 2307.
9. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
10. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457.
11. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction-long-term results. Am J Transplant 2005; 5: 2539.
12. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754.
13. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005; 5: 1347.
14. Bartosh SM, Knechtle SJ, Sollinger HW. Campath-1H use in pediatric renal transplantation. Am J Transplant 2005; 5: 1569.
15. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426.
16. Knechtle SJ, Pirsch JD, H. Fechner JJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
17. Malek SK, Obmann MA, Gotoff RA, Foltzer MA, Hartle JE, Potdar S. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006; 81: 17.
18. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6: 2409.
19. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765.